首页 > 最新文献

Intelligent Pharmacy最新文献

英文 中文
The importance of in-silico studies in drug discovery 药物发现中硅学研究的重要性
Pub Date : 2024-08-01 DOI: 10.1016/j.ipha.2024.01.010
Miah Roney, Mohd Fadhlizil Fasihi Mohd Aluwi

The use of in-silico research in drug development is growing. Aspects of drug discovery and development, such as virtual ligand screening and profiling, target and lead finding, and compound library creation, are simulated by computational approaches. Databases, pharmacophores, homology models, quantitative structure–activity connections, machine learning, data mining, network analysis tools, and computer-based data analysis tools are examples of in-silico techniques. These techniques are mostly applied in conjunction with the production of in vitro data to build models that facilitate the identification and refinement of new compounds by providing insight into their features related to absorption, distribution, metabolism, and excretion.

在药物开发过程中,硅内研究的应用日益广泛。药物发现和开发的各个方面,如虚拟配体筛选和剖析、靶点和先导物的发现以及化合物库的创建,都是通过计算方法模拟进行的。数据库、药理学、同源模型、定量结构-活性联系、机器学习、数据挖掘、网络分析工具和基于计算机的数据分析工具都是硅学技术的实例。这些技术大多与体外数据结合使用,通过深入了解新化合物在吸收、分布、代谢和排泄方面的特点,建立有助于识别和改进新化合物的模型。
{"title":"The importance of in-silico studies in drug discovery","authors":"Miah Roney,&nbsp;Mohd Fadhlizil Fasihi Mohd Aluwi","doi":"10.1016/j.ipha.2024.01.010","DOIUrl":"10.1016/j.ipha.2024.01.010","url":null,"abstract":"<div><p>The use of in-silico research in drug development is growing. Aspects of drug discovery and development, such as virtual ligand screening and profiling, target and lead finding, and compound library creation, are simulated by computational approaches. Databases, pharmacophores, homology models, quantitative structure–activity connections, machine learning, data mining, network analysis tools, and computer-based data analysis tools are examples of in-silico techniques. These techniques are mostly applied in conjunction with the production of in vitro data to build models that facilitate the identification and refinement of new compounds by providing insight into their features related to absorption, distribution, metabolism, and excretion.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 578-579"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X24000200/pdfft?md5=a7867f2e1e88920b4714446ae3598312&pid=1-s2.0-S2949866X24000200-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bioactive peptides derived from the enzymatic hydrolysis of cowhide collagen for the potential treatment of atherosclerosis: A computational approach 通过酶水解牛皮胶原蛋白提取的生物活性肽可用于治疗动脉粥样硬化:一种计算方法
Pub Date : 2024-08-01 DOI: 10.1016/j.ipha.2024.05.004

Cowhide collagen hydrolysates (CCHs) are peptides and amino acids obtained from the partial hydrolysis of collagen. These have numerous potential applications in the food, biomedical, and pharmaceutical industries. The study analyzed the physicochemical, antioxidant, and anti-atherosclerosis properties of collagen hydrolysates (CCHs) from cowhide using in silico methods. Proteins were identified in silico based on their molecular weights and origin from the protein database (UniProtKB). Using bioinformatics tools, numerous physicochemical properties (toxicity and amino acid composition) were determined. The identified proteins were subsequently subjected to an in silico enzymatic hydrolysis using pepsin, thermolysin, and proteinase K. The peptides obtained were characterized. Molecular docking was conducted between the peptides generated in silico and the three target enzymes (3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) reductase, cyclooxygenase-2, and Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase). Two cowhide collagens were identified, F1MJQ6 and G3MZI7, with molecular weights of 172,076 and 184,867 ​Da, respectively. A compositional analysis of F1MJQ6 and G3MZI7 revealed the significant presence of glycine residues at 25% and 23%, and proline residues at 16% and 18%, respectively. The G3MZI7 and F1MJQ6 proteins exhibited a high concentration of both essential and semi-essential amino acids. The molecular docking results indicate that the antioxidant peptides ADF, PHF, and LW (novel potential anti-atherosclerosis peptides released by enzymatic hydrolysis with pepsin, thermolysin, and proteinase K) are the most promising candidates for further development as inhibitors of HMG-CoA reductase, cyclo-oxygenase-2, and NADPH oxidase. In silico analysis revealed that cowhide collagen hydrolysates exhibited particularly significant antioxidant and anti-atherosclerosis properties.

牛皮胶原水解物(CCHs)是通过部分水解胶原蛋白获得的肽和氨基酸。这些物质在食品、生物医学和制药行业有许多潜在应用。本研究采用硅学方法分析了牛皮胶原水解物(CCHs)的理化、抗氧化和抗动脉粥样硬化特性。根据蛋白质数据库(UniProtKB)中蛋白质的分子量和来源,对蛋白质进行了硅学鉴定。利用生物信息学工具确定了许多理化性质(毒性和氨基酸组成)。随后,使用胃蛋白酶、热溶酶和蛋白酶 K 对鉴定出的蛋白质进行了模拟酶水解。在硅学中生成的肽与三种目标酶(3-羟基-3-甲基戊二酰-CoA(HMG-CoA)还原酶、环氧化酶-2 和烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶)之间进行了分子对接。鉴定出了两种牛皮胶原,分别为 F1MJQ6 和 G3MZI7,分子量分别为 172,076 和 184,867 Da。对 F1MJQ6 和 G3MZI7 的成分分析表明,它们含有大量甘氨酸残基,分别占 25% 和 23%,以及脯氨酸残基,分别占 16% 和 18%。G3MZI7 和 F1MJQ6 蛋白含有大量必需氨基酸和半必需氨基酸。分子对接结果表明,抗氧化肽 ADF、PHF 和 LW(通过胃蛋白酶、热溶酶和蛋白酶 K 的酶水解作用释放的新型潜在抗动脉粥样硬化肽)是最有希望进一步开发为 HMG-CoA 还原酶、环氧化酶-2 和 NADPH 氧化酶抑制剂的候选物质。硅学分析表明,牛皮胶原水解物具有特别显著的抗氧化和抗动脉粥样硬化特性。
{"title":"Bioactive peptides derived from the enzymatic hydrolysis of cowhide collagen for the potential treatment of atherosclerosis: A computational approach","authors":"","doi":"10.1016/j.ipha.2024.05.004","DOIUrl":"10.1016/j.ipha.2024.05.004","url":null,"abstract":"<div><p>Cowhide collagen hydrolysates (CCHs) are peptides and amino acids obtained from the partial hydrolysis of collagen. These have numerous potential applications in the food, biomedical, and pharmaceutical industries. The study analyzed the physicochemical, antioxidant, and anti-atherosclerosis properties of collagen hydrolysates (CCHs) from cowhide using <em>in silico</em> methods. Proteins were identified <em>in silico</em> based on their molecular weights and origin from the protein database (UniProtKB). Using bioinformatics tools, numerous physicochemical properties (toxicity and amino acid composition) were determined. The identified proteins were subsequently subjected to an <em>in silico</em> enzymatic hydrolysis using pepsin, thermolysin, and proteinase K. The peptides obtained were characterized. Molecular docking was conducted between the peptides generated <em>in silico</em> and the three target enzymes (3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) reductase, cyclooxygenase-2, and Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase). Two cowhide collagens were identified, F1MJQ6 and G3MZI7, with molecular weights of 172,076 and 184,867 ​Da, respectively. A compositional analysis of F1MJQ6 and G3MZI7 revealed the significant presence of glycine residues at 25% and 23%, and proline residues at 16% and 18%, respectively. The G3MZI7 and F1MJQ6 proteins exhibited a high concentration of both essential and semi-essential amino acids. The molecular docking results indicate that the antioxidant peptides ADF, PHF, and LW (novel potential anti-atherosclerosis peptides released by enzymatic hydrolysis with pepsin, thermolysin, and proteinase K) are the most promising candidates for further development as inhibitors of HMG-CoA reductase, cyclo-oxygenase-2, and NADPH oxidase. <em>In silico</em> analysis revealed that cowhide collagen hydrolysates exhibited particularly significant antioxidant and anti-atherosclerosis properties.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 456-466"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X24000649/pdfft?md5=cc419310465d774ff59c2aac885be063&pid=1-s2.0-S2949866X24000649-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141037354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
QSAR application of natural therapeutics inhibitors against Alzheimer's disease through in-silico virtual-screening, docking-simulation, molecular dynamics, and pharmacokinetic prediction analysis 通过室内虚拟筛选、对接模拟、分子动力学和药代动力学预测分析,对阿尔茨海默病天然治疗抑制剂的 QSAR 应用研究
Pub Date : 2024-08-01 DOI: 10.1016/j.ipha.2023.12.004
Abduljelil Ajala , Adamu Uzairu , Gideon A. Shallangwa , Stephen E Abechi , Abdullahi Bello Umar , Ibrahim A Abdulganiyyu , Ramith Ramu , Naveen Kumar

Alzheimer's disease (AD) is a brain disorder that is known to be one of the deadliest diseases affecting humanity, especially adults from the age of sixty (60) years and above. It mostly affects thinking ability, behaviour and social skills, eventually, AD causes the brain to shrink and brain cells to die. To curb the menace of this disease, virtual screening of potent, non-toxic hybrid natural therapeutic inhibitors was performed on some inhibitors of AD. We performed simulations on the screened compounds and predicted their druggability. A model with satisfactory statistical properties was developed in this study. The ligands underwent molecular docking, C-19 exhibited the highest docked score of −12.8 ​kcal/mol against the target, while the referenced compound (harmine) indicated the lowest docked score of −8.2 ​kcal/mol. The docked complex was validated using molecular dynamic simulations. Trajectory plots of C-19 were obtained and found to be stable. C-19 was stable during the 100 ns intervals which implies that the compounds were better than the referenced compound. In addition, ADMET has demonstrated that these ligands have good pharmacokinetic properties. All the evaluations were more comprehensive and beneficial to researchers and the medical community as outstanding results were obtained.

阿尔茨海默病(AD)是一种脑部疾病,是影响人类,尤其是六十(60)岁以上成年人的最致命疾病之一。它主要影响思维能力、行为和社交能力,最终导致大脑萎缩和脑细胞死亡。为了遏制这种疾病的威胁,我们对一些抑制注意力缺失症的有效、无毒混合天然治疗抑制剂进行了虚拟筛选。我们对筛选出的化合物进行了模拟,并预测了它们的可药用性。这项研究建立了一个具有令人满意的统计特性的模型。配体进行了分子对接,C-19与目标物的对接得分最高,为-12.8 kcal/mol,而参考化合物(harmine)的对接得分最低,为-8.2 kcal/mol。通过分子动力学模拟对对接复合物进行了验证。获得了 C-19 的轨迹图,并发现它是稳定的。C-19 在 100 毫微秒的时间间隔内保持稳定,这意味着化合物的性能优于参考化合物。此外,ADMET 证明这些配体具有良好的药代动力学特性。所有的评估都比较全面,取得了出色的结果,对研究人员和医学界都很有益。
{"title":"QSAR application of natural therapeutics inhibitors against Alzheimer's disease through in-silico virtual-screening, docking-simulation, molecular dynamics, and pharmacokinetic prediction analysis","authors":"Abduljelil Ajala ,&nbsp;Adamu Uzairu ,&nbsp;Gideon A. Shallangwa ,&nbsp;Stephen E Abechi ,&nbsp;Abdullahi Bello Umar ,&nbsp;Ibrahim A Abdulganiyyu ,&nbsp;Ramith Ramu ,&nbsp;Naveen Kumar","doi":"10.1016/j.ipha.2023.12.004","DOIUrl":"10.1016/j.ipha.2023.12.004","url":null,"abstract":"<div><p>Alzheimer's disease (AD) is a brain disorder that is known to be one of the deadliest diseases affecting humanity, especially adults from the age of sixty (60) years and above. It mostly affects thinking ability, behaviour and social skills, eventually, AD causes the brain to shrink and brain cells to die. To curb the menace of this disease, virtual screening of potent, non-toxic hybrid natural therapeutic inhibitors was performed on some inhibitors of AD. We performed simulations on the screened compounds and predicted their druggability. A model with satisfactory statistical properties was developed in this study. The ligands underwent molecular docking, C-19 exhibited the highest docked score of −12.8 ​kcal/mol against the target, while the referenced compound (harmine) indicated the lowest docked score of −8.2 ​kcal/mol. The docked complex was validated using molecular dynamic simulations. Trajectory plots of C-19 were obtained and found to be stable. C-19 was stable during the 100 ns intervals which implies that the compounds were better than the referenced compound. In addition, ADMET has demonstrated that these ligands have good pharmacokinetic properties. All the evaluations were more comprehensive and beneficial to researchers and the medical community as outstanding results were obtained.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 505-515"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23001302/pdfft?md5=92629a1bf2eae34b48dd7013a0e45788&pid=1-s2.0-S2949866X23001302-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The fermented milk can be a natural ally against obesity? Investigation of bovine milk fermentation by Lacticaseibacillus casei LBC 237, screening, and In silico predictions of bioactive peptides for obesity control 发酵牛奶能否成为防治肥胖症的天然盟友?牛乳发酵乳酸酶杆菌 LBC 237 的研究、筛选以及用于控制肥胖的生物活性肽的硅学预测
Pub Date : 2024-08-01 DOI: 10.1016/j.ipha.2024.05.009
Emyr Hiago Bellaver , Ingrid Militão da Costa , Eduarda Eliza Redin , Liziane Schittler Moroni , Aniela Pinto Kempka

The increasing quest for therapeutic alternatives in treating non-communicable chronic diseases like obesity has propelled research into bioactive peptides, with a particular focus on milk due to its rich protein composition and associated health benefits. Milk fermentation, a traditional process in dairy production, enhances the bioactivity of peptides, broadening their potential therapeutic uses. This study investigated the anti-obesity potential of peptides from bovine milk fermented by Lacticaseibacillus casei LBC 237, identifying 143 peptides, notably LGPV and EVPMP. In silico analyses revealed that LGPV and EVPMP biopeptides exhibited significant interactions with target proteins, employing various molecular interactions such as Van der Waals forces, hydrogen bonds, and electrostatic interactions. These peptides shared common binding sites in some enzymes, suggesting a similar mode of interaction between molecule and target protein, akin to key pharmaceuticals recommended for treating these pathologies. Furthermore, amino acid characteristics present in the peptides, including hydrophobic residues like Leucine, Glutamate, Valine, and Proline, proved essential for their bioactive and inhibitory activities. These findings highlight the potential of LGPV and EVPMP biopeptides as therapeutic agents in managing obesity and metabolic disorders. They provide important insights into their mechanisms of action, paving the way for future research to apply them practically in preventing and treating metabolic conditions.

在治疗肥胖症等非传染性慢性疾病方面,人们越来越多地寻求替代疗法,这推动了对生物活性肽的研究,尤其是对牛奶的研究,因为牛奶中含有丰富的蛋白质成分,并具有相关的健康益处。牛奶发酵是乳制品生产的传统工艺,可增强肽的生物活性,扩大其潜在的治疗用途。这项研究调查了由乳酸酶杆菌 LBC 237 发酵的牛乳中肽的抗肥胖潜力,确定了 143 种肽,特别是 LGPV 和 EVPMP。硅学分析表明,LGPV 和 EVPMP 生物肽通过范德华力、氢键和静电作用等各种分子相互作用,与目标蛋白质发生了显著的相互作用。这些肽在某些酶中具有共同的结合位点,表明分子与目标蛋白之间具有类似的相互作用模式,类似于治疗这些病症的关键药物。此外,肽中存在的氨基酸特征,包括亮氨酸、谷氨酸、缬氨酸和脯氨酸等疏水残基,被证明对其生物活性和抑制活性至关重要。这些发现凸显了 LGPV 和 EVPMP 生物肽作为治疗肥胖症和代谢紊乱药物的潜力。这些研究为了解它们的作用机理提供了重要依据,为今后将它们实际应用于预防和治疗代谢疾病的研究铺平了道路。
{"title":"The fermented milk can be a natural ally against obesity? Investigation of bovine milk fermentation by Lacticaseibacillus casei LBC 237, screening, and In silico predictions of bioactive peptides for obesity control","authors":"Emyr Hiago Bellaver ,&nbsp;Ingrid Militão da Costa ,&nbsp;Eduarda Eliza Redin ,&nbsp;Liziane Schittler Moroni ,&nbsp;Aniela Pinto Kempka","doi":"10.1016/j.ipha.2024.05.009","DOIUrl":"10.1016/j.ipha.2024.05.009","url":null,"abstract":"<div><p>The increasing quest for therapeutic alternatives in treating non-communicable chronic diseases like obesity has propelled research into bioactive peptides, with a particular focus on milk due to its rich protein composition and associated health benefits. Milk fermentation, a traditional process in dairy production, enhances the bioactivity of peptides, broadening their potential therapeutic uses. This study investigated the anti-obesity potential of peptides from bovine milk fermented by <em>Lacticaseibacillus casei</em> LBC 237, identifying 143 peptides, notably LGPV and EVPMP. <em>In silico</em> analyses revealed that LGPV and EVPMP biopeptides exhibited significant interactions with target proteins, employing various molecular interactions such as Van der Waals forces, hydrogen bonds, and electrostatic interactions. These peptides shared common binding sites in some enzymes, suggesting a similar mode of interaction between molecule and target protein, akin to key pharmaceuticals recommended for treating these pathologies. Furthermore, amino acid characteristics present in the peptides, including hydrophobic residues like Leucine, Glutamate, Valine, and Proline, proved essential for their bioactive and inhibitory activities. These findings highlight the potential of LGPV and EVPMP biopeptides as therapeutic agents in managing obesity and metabolic disorders. They provide important insights into their mechanisms of action, paving the way for future research to apply them practically in preventing and treating metabolic conditions.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 467-484"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X24000698/pdfft?md5=f1aaa04a5548fb0a283fe00c0055a356&pid=1-s2.0-S2949866X24000698-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the intricacies of phytate antinutrients in millets and their therapeutic implications in breast cancer 揭示黍米中植酸抗性营养素的复杂性及其对乳腺癌的治疗意义
Pub Date : 2024-08-01 DOI: 10.1016/j.ipha.2023.12.005

Breast cancer remains a significant global health concern, necessitating the exploration of novel preventive and therapeutic strategies. Dietary interventions have gained substantial attention due to their potential to modulate cancer risk and progression. Millets, a group of small-seeded grasses, have emerged as promising candidates in this regard, owing to their rich nutritional composition and diverse bioactive compounds. Among these bioactive compounds, phytate antinutrients have garnered considerable interest for their potential health benefits. This review aims to unravel the intricacies of phytate antinutrients in millets and their therapeutic implications in breast cancer. Phytates are naturally occurring compounds present in various plant-based foods, including millets, and are known for their ability to chelate minerals and inhibit their bioavailability. However, recent research has shed light on the multifaceted properties of phytates, highlighting their potential as functional bioactive molecules. Phytates exhibit various anticancer properties, including “antioxidant, anti-inflammatory, and antiproliferative effects”, which have been shown to inhibit the growth and progression of breast cancer cells. Additionally, phytates have been reported to modulate key signaling pathways involved in cancer development, such as PI3K/Akt, MAPK, and NF-κB, thereby exerting their anticancer effects. Moreover, phytates demonstrate the potential to enhance the efficacy of conventional breast cancer treatments, such as chemotherapy and radiation therapy, while mitigating their adverse effects. Furthermore, the bioavailability and metabolism of phytates are complex processes influenced by factors such as food processing, gut microbiota composition, and genetic variations. Understanding these intricacies is crucial for harnessing the full potential of phytates in breast cancer prevention and treatment. In conclusion, this review provides a comprehensive overview of the intricate roles of phytate antinutrients in millets and their therapeutic implications in breast cancer. The findings suggest that millets, as a rich source of phytates, could be incorporated into dietary strategies to reduce breast cancer risk and complement existing therapeutic approaches. However, further research is warranted to elucidate the precise mechanisms of action, optimal dosage, and potential synergistic effects with other bioactive compounds. The information that is given here is supported by accurate facts and arguments that have undergone rigorous scrutiny.

乳腺癌仍然是全球关注的重大健康问题,因此有必要探索新的预防和治疗策略。由于膳食干预具有调节癌症风险和进展的潜力,因此受到了广泛关注。黍类是一类小种子禾本科植物,由于其丰富的营养成分和多种生物活性化合物,已成为这方面有希望的候选者。在这些生物活性化合物中,植酸抗性营养素因其潜在的健康益处而备受关注。本综述旨在揭示黍中植酸抗性营养素的复杂性及其对乳腺癌的治疗意义。植酸盐是存在于包括黍米在内的各种植物性食物中的天然化合物,因其能够螯合矿物质并抑制矿物质的生物利用率而闻名。然而,最近的研究揭示了植酸盐的多方面特性,凸显了它们作为功能性生物活性分子的潜力。植酸盐具有多种抗癌特性,包括 "抗氧化、抗炎和抗增殖作用",已被证明可抑制乳腺癌细胞的生长和恶化。此外,据报道,植酸盐还能调节涉及癌症发展的关键信号通路,如 PI3K/Akt、MAPK 和 NF-κB,从而发挥抗癌作用。此外,植酸盐还具有提高化疗和放疗等传统乳腺癌治疗方法疗效的潜力,同时减轻其不良反应。此外,植酸盐的生物利用率和新陈代谢是一个复杂的过程,受食品加工、肠道微生物群组成和遗传变异等因素的影响。了解这些错综复杂的因素对于充分发挥植酸盐在乳腺癌预防和治疗中的潜力至关重要。总之,本综述全面概述了黍米中植酸抗性营养素的复杂作用及其对乳腺癌的治疗意义。研究结果表明,作为植酸盐的丰富来源,黍米可被纳入膳食策略,以降低乳腺癌风险并补充现有的治疗方法。不过,还需要进一步研究,以阐明其确切的作用机制、最佳剂量以及与其他生物活性化合物的潜在协同效应。本文所提供的信息都是经过严格审查的准确事实和论据。
{"title":"Unveiling the intricacies of phytate antinutrients in millets and their therapeutic implications in breast cancer","authors":"","doi":"10.1016/j.ipha.2023.12.005","DOIUrl":"10.1016/j.ipha.2023.12.005","url":null,"abstract":"<div><p>Breast cancer remains a significant global health concern, necessitating the exploration of novel preventive and therapeutic strategies. Dietary interventions have gained substantial attention due to their potential to modulate cancer risk and progression. Millets, a group of small-seeded grasses, have emerged as promising candidates in this regard, owing to their rich nutritional composition and diverse bioactive compounds. Among these bioactive compounds, phytate antinutrients have garnered considerable interest for their potential health benefits. This review aims to unravel the intricacies of phytate antinutrients in millets and their therapeutic implications in breast cancer. Phytates are naturally occurring compounds present in various plant-based foods, including millets, and are known for their ability to chelate minerals and inhibit their bioavailability. However, recent research has shed light on the multifaceted properties of phytates, highlighting their potential as functional bioactive molecules. Phytates exhibit various anticancer properties, including “antioxidant, anti-inflammatory, and antiproliferative effects”, which have been shown to inhibit the growth and progression of breast cancer cells. Additionally, phytates have been reported to modulate key signaling pathways involved in cancer development, such as PI3K/Akt, MAPK, and NF-κB, thereby exerting their anticancer effects. Moreover, phytates demonstrate the potential to enhance the efficacy of conventional breast cancer treatments, such as chemotherapy and radiation therapy, while mitigating their adverse effects. Furthermore, the bioavailability and metabolism of phytates are complex processes influenced by factors such as food processing, gut microbiota composition, and genetic variations. Understanding these intricacies is crucial for harnessing the full potential of phytates in breast cancer prevention and treatment. In conclusion, this review provides a comprehensive overview of the intricate roles of phytate antinutrients in millets and their therapeutic implications in breast cancer. The findings suggest that millets, as a rich source of phytates, could be incorporated into dietary strategies to reduce breast cancer risk and complement existing therapeutic approaches. However, further research is warranted to elucidate the precise mechanisms of action, optimal dosage, and potential synergistic effects with other bioactive compounds. The information that is given here is supported by accurate facts and arguments that have undergone rigorous scrutiny.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 516-527"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23001314/pdfft?md5=7a60ada6a931260ba11551212d20f20c&pid=1-s2.0-S2949866X23001314-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139190766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of immunomodulatory therapies with COVID-19 mortality in rheumatoid arthritis: An analysis of the FDA adverse event reporting system 类风湿关节炎患者的免疫调节疗法与 COVID-19 死亡率之间的关系:对 FDA 不良事件报告系统的分析
Pub Date : 2024-08-01 DOI: 10.1016/j.ipha.2024.05.003

Background

The COVID-19 pandemic significantly affects patients with RA and other rheumatic diseases. Our study aims to explore the factors associated with COVID-19-related fatality among Rheumatoid Arthritis (RA) patients, especially immunomodulatory therapies, using the international Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).

Methods

Reportes from FAERS were extracted from February 2020 to September 2022, and uesd for this cross-sectional analysis. The investigative outcome was COVID-19-related death. Age, sex, region, event date, and immunomodulatory medications classies were included as co-variates in multivariable logistic regression. In view of the different targeting and affinity of individual JAKi, Tofacitinib, Upadacitinib and Baricitinib was respectively analyzed.

Results

In all, 3808 cases (mean age 58.85 years, 82.8% female), 267 (7.0%) died. JAKi therapies (41.2%), followed by TNFi (37.7%), IL-1i (12.2%), IL-6i (4.1%) and Anti-CD20 (3%) were reported. Risk factors associated with COVID-19-related death in RA patients were age (odds ratio [OR]: 1.06; 95% confidence interval [CI]: 1.05–1.08; p ​< ​0.01), male sex (1.71, 1.26–2.33; p ​= ​0.01) and anti-CD20 therapies (5.05; 1.40–18.19; p ​= ​0.013). With TNFi conference, anti-CD20 was still a risk predictor (4.29; 2.39–7.70; p ​< ​0.01). Other DMARDs except for anti-CD20, did not confer a significant association with mortality, compared with csDMARDs or TNFi. Individual JAKi showed no obvious difference in the risk of death, compared with csDMARDs or TNFis.

Conclusions

Conclusions Using FAERS open access data for risk prediction of death, anti-CD20 therapies were recognized as a risk factor for COVID-19-related fatalities among RA patients, other immunomodulatory therapies were not associated with mortality, compared with csDMARDs or TNFis.

背景COVID-19大流行严重影响了类风湿关节炎和其他风湿性疾病患者。我们的研究旨在利用国际食品药品管理局(FDA)的不良事件报告系统(FAERS),探讨类风湿关节炎(RA)患者中与 COVID-19 相关死亡的相关因素,尤其是免疫调节疗法。研究结果为与 COVID-19 相关的死亡。在多变量逻辑回归中,年龄、性别、地区、事件发生日期和免疫调节药物分类被列为共变因素。结果 在所有 3808 例病例(平均年龄 58.85 岁,82.8% 为女性)中,有 267 例(7.0%)死亡。据报道,JAKi疗法占41.2%,其次是TNFi疗法(37.7%)、IL-1i疗法(12.2%)、IL-6i疗法(4.1%)和抗CD20疗法(3%)。与COVID-19相关的RA患者死亡的风险因素是年龄(几率比[OR]:1.06;95% 置信区间 [CI]:1.05-1.08; p < 0.01)、男性(1.71, 1.26-2.33; p = 0.01)和抗CD20疗法(5.05; 1.40-18.19; p = 0.013)。在 TNFi 会议上,抗 CD20 仍是一个风险预测因子(4.29;2.39-7.70;p <;0.01)。与csDMARDs或TNFi相比,除抗CD20外,其他DMARDs与死亡率无显著相关性。结论 使用FAERS开放数据进行死亡风险预测,抗CD20疗法被认为是RA患者COVID-19相关死亡的风险因素,与csDMARDs或TNFis相比,其他免疫调节疗法与死亡率无关。
{"title":"Association of immunomodulatory therapies with COVID-19 mortality in rheumatoid arthritis: An analysis of the FDA adverse event reporting system","authors":"","doi":"10.1016/j.ipha.2024.05.003","DOIUrl":"10.1016/j.ipha.2024.05.003","url":null,"abstract":"<div><h3>Background</h3><p>The COVID-19 pandemic significantly affects patients with RA and other rheumatic diseases. Our study aims to explore the factors associated with COVID-19-related fatality among Rheumatoid Arthritis (RA) patients, especially immunomodulatory therapies, using the international Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).</p></div><div><h3>Methods</h3><p>Reportes from FAERS were extracted from February 2020 to September 2022, and uesd for this cross-sectional analysis. The investigative outcome was COVID-19-related death. Age, sex, region, event date, and immunomodulatory medications classies were included as co-variates in multivariable logistic regression. In view of the different targeting and affinity of individual JAKi, Tofacitinib, Upadacitinib and Baricitinib was respectively analyzed.</p></div><div><h3>Results</h3><p>In all, 3808 cases (mean age 58.85 years, 82.8% female), 267 (7.0%) died. JAKi therapies (41.2%), followed by TNFi (37.7%), IL-1i (12.2%), IL-6i (4.1%) and Anti-CD20 (3%) were reported. Risk factors associated with COVID-19-related death in RA patients were age (odds ratio [OR]: 1.06; 95% confidence interval [CI]: 1.05–1.08; <em>p</em> ​&lt; ​0.01), male sex (1.71, 1.26–2.33; <em>p</em> ​= ​0.01) and anti-CD20 therapies (5.05; 1.40–18.19; <em>p</em> ​= ​0.013). With TNFi conference, anti-CD20 was still a risk predictor (4.29; 2.39–7.70; <em>p</em> ​&lt; ​0.01). Other DMARDs except for anti-CD20, did not confer a significant association with mortality, compared with csDMARDs or TNFi. Individual JAKi showed no obvious difference in the risk of death, compared with csDMARDs or TNFis.</p></div><div><h3>Conclusions</h3><p>Conclusions Using FAERS open access data for risk prediction of death, anti-CD20 therapies were recognized as a risk factor for COVID-19-related fatalities among RA patients, other immunomodulatory therapies were not associated with mortality, compared with csDMARDs or TNFis.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 451-455"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X2400056X/pdfft?md5=6bd80a6185e4a935d2ab2cce768c6ee4&pid=1-s2.0-S2949866X2400056X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141047696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Telmisartan-loaded liposomes: An innovative weapon against breast cancer 替米沙坦脂质体:抗击乳腺癌的创新武器
Pub Date : 2024-08-01 DOI: 10.1016/j.ipha.2024.01.001

This study focuses on the development of a liposomal preparation for the targeted delivery of Telmisartan in the context of breast cancer treatment. Telmisartan, a pharmaceutical agent with potential anticancer properties, has been encapsulated within liposomes, lipid-based vesicles known for their capacity to enhance drug delivery and improve therapeutic outcomes. The formulation and characterization of Telmisartan-loaded liposomes were conducted, evaluating factors such as size, shape, and drug release profiles. The findings demonstrate that the liposomal preparation effectively encapsulates Telmisartan, maintaining its pharmacological properties. The development of such liposomal formulations holds promise for advancing breast cancer therapies, offering the potential for enhanced treatment efficacy and reduced side effects. This research contributes to the ongoing efforts to explore innovative drug delivery strategies in the realm of breast cancer treatment. Breast cancer is a pervasive and challenging malignancy affecting women worldwide. In the quest for more effective and targeted treatment approaches, the development of liposomal preparations for delivering therapeutic agents to breast cancer cells has emerged as a promising avenue. Telmisartan, originally recognized for its antihypertensive properties, has been increasingly investigated for its potential anticancer effects. This study delves into the design and evaluation of a liposomal formulation for Telmisartan, aiming to enhance its therapeutic potential in breast cancer. The formulation process involved the encapsulation of Telmisartan within lipid-based liposomes, which are well-known for their ability to carry a variety of drugs, protect them from degradation, and enhance their selective delivery to tumor cells.

本研究的重点是开发一种脂质体制剂,用于在乳腺癌治疗中靶向输送替米沙坦。替米沙坦是一种具有潜在抗癌特性的药物,已被包裹在脂质体中,脂质体是一种以脂质为基础的囊泡,因其具有增强药物输送和改善治疗效果的能力而闻名。研究人员对载入替米沙坦的脂质体进行了配制和表征,评估了其大小、形状和药物释放情况等因素。研究结果表明,脂质体制剂能有效包裹替米沙坦,保持其药理特性。开发这种脂质体制剂有望促进乳腺癌疗法的发展,为提高疗效和减少副作用提供了可能。这项研究有助于在乳腺癌治疗领域不断探索创新的给药策略。乳腺癌是一种影响全球妇女的普遍而具有挑战性的恶性肿瘤。为了寻求更有效、更有针对性的治疗方法,开发脂质体制剂以向乳腺癌细胞输送治疗药物已成为一条前景广阔的途径。替米沙坦(Telmisartan)最初被认为具有抗高血压的特性,但其潜在的抗癌作用也受到越来越多的研究。本研究深入探讨了替米沙坦脂质体制剂的设计和评估,旨在提高其对乳腺癌的治疗潜力。制剂过程包括将替米沙坦封装在脂质体中,脂质体因其能够携带多种药物、保护药物不被降解以及增强对肿瘤细胞的选择性递送而闻名。
{"title":"Telmisartan-loaded liposomes: An innovative weapon against breast cancer","authors":"","doi":"10.1016/j.ipha.2024.01.001","DOIUrl":"10.1016/j.ipha.2024.01.001","url":null,"abstract":"<div><p>This study focuses on the development of a liposomal preparation for the targeted delivery of Telmisartan in the context of breast cancer treatment. Telmisartan, a pharmaceutical agent with potential anticancer properties, has been encapsulated within liposomes, lipid-based vesicles known for their capacity to enhance drug delivery and improve therapeutic outcomes. The formulation and characterization of Telmisartan-loaded liposomes were conducted, evaluating factors such as size, shape, and drug release profiles. The findings demonstrate that the liposomal preparation effectively encapsulates Telmisartan, maintaining its pharmacological properties. The development of such liposomal formulations holds promise for advancing breast cancer therapies, offering the potential for enhanced treatment efficacy and reduced side effects. This research contributes to the ongoing efforts to explore innovative drug delivery strategies in the realm of breast cancer treatment. Breast cancer is a pervasive and challenging malignancy affecting women worldwide. In the quest for more effective and targeted treatment approaches, the development of liposomal preparations for delivering therapeutic agents to breast cancer cells has emerged as a promising avenue. Telmisartan, originally recognized for its antihypertensive properties, has been increasingly investigated for its potential anticancer effects. This study delves into the design and evaluation of a liposomal formulation for Telmisartan, aiming to enhance its therapeutic potential in breast cancer. The formulation process involved the encapsulation of Telmisartan within lipid-based liposomes, which are well-known for their ability to carry a variety of drugs, protect them from degradation, and enhance their selective delivery to tumor cells.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 565-570"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X24000017/pdfft?md5=1596786390e538b379ae6753631be0ac&pid=1-s2.0-S2949866X24000017-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139539568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acalypha wilkesiana L - A potential anti-stearoyl-CoA desaturase agent: Insilico and network pharmacology studies Acalypha wilkesiana L - 一种潜在的抗硬脂酰-CoA 去饱和酶制剂:内部和网络药理学研究
Pub Date : 2024-08-01 DOI: 10.1016/j.ipha.2023.12.007

The activity of Seborrheic dermatitis on the skin of children still remains of the dermatoses of male and female babies in the early days of their existence. Acalypha wilkesiana L have been employed by mothers to combat Seborrheic dermatitis, yet, the descriptors responsible for such activity as well as the nonbonding interactions between the selected phytochemicals and stearoyl-CoA desaturase has not been explored. The studied compounds were optimized using Spartan’14 software as well as molecular operating environments (MOE) for docking, Cytoscape software for compound-protein interaction network, Gromacs for molecular dynamic simulation as well ADMETSar for pharmacokinetics studies. The selected compounds proved to have anti-stearoyl-CoA desaturase properties via the calculated descriptors obtained from the chemical compounds obtained from Acalypha wilkesiana L as well as from the result from molecular modeling studies. The Pharmacokinetics results were observed and reported appropriately.

儿童皮肤上的脂溢性皮炎仍然是男女婴儿出生初期的皮肤病之一。母亲们一直在使用 Acalypha wilkesiana L 来防治脂溢性皮炎,但尚未探索导致这种活性的描述因子以及所选植物化学物质与硬脂酰-CoA 去饱和酶之间的非键相互作用。研究人员使用 Spartan'14 软件和分子操作环境(MOE)对所研究的化合物进行了优化对接,使用 Cytoscape 软件建立了化合物-蛋白质相互作用网络,使用 Gromacs 进行了分子动力学模拟,并使用 ADMETSar 进行了药代动力学研究。通过计算从 Acalypha wilkesiana L 中获得的化合物的描述符以及分子建模研究的结果,证明所选化合物具有抗硬脂酰-CoA 去饱和酶的特性。观察并适当报告了药代动力学结果。
{"title":"Acalypha wilkesiana L - A potential anti-stearoyl-CoA desaturase agent: Insilico and network pharmacology studies","authors":"","doi":"10.1016/j.ipha.2023.12.007","DOIUrl":"10.1016/j.ipha.2023.12.007","url":null,"abstract":"<div><p>The activity of Seborrheic dermatitis on the skin of children still remains of the dermatoses of male and female babies in the early days of their existence. <em>Acalypha wilkesiana</em> L have been employed by mothers to combat Seborrheic dermatitis, yet, the descriptors responsible for such activity as well as the nonbonding interactions between the selected phytochemicals and stearoyl-CoA desaturase has not been explored. The studied compounds were optimized using Spartan’14 software as well as molecular operating environments (MOE) for docking, Cytoscape software for compound-protein interaction network, Gromacs for molecular dynamic simulation as well ADMETSar for pharmacokinetics studies. The selected compounds proved to have anti-stearoyl-CoA desaturase properties via the calculated descriptors obtained from the chemical compounds obtained from <em>Acalypha wilkesiana</em> L as well as from the result from molecular modeling studies. The Pharmacokinetics results were observed and reported appropriately.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 540-553"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23001338/pdfft?md5=bf21b043b1b223a595481f0223babd84&pid=1-s2.0-S2949866X23001338-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139191506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing oral drug delivery: The science of fast dissolving tablets (FDTs) 推进口服给药:快速溶解片剂(FDT)的科学原理
Pub Date : 2024-08-01 DOI: 10.1016/j.ipha.2024.01.011

The field of oral drug delivery has witnessed significant advancements, with a focus on developing innovative formulations to address challenges associated with traditional dosage forms, especially for patients with difficulties in swallowing. Fast Dissolving Tablets (FDTs) have emerged as a promising class of tablets designed to rapidly disintegrate or dissolve in saliva, providing a convenient and patient-friendly alternative for various populations.

This article explores the unique properties, advantages, and potential applications of FDTs, emphasizing their role in overcoming challenges posed by conventional oral drug delivery systems. FDTs offer rapid dissolution within 15-120 seconds in the buccal cavity, facilitating direct absorption through the buccal mucosa and ensuring quick therapeutic effects. This characteristic proves particularly beneficial for individuals facing swallowing challenges, such as pediatric and geriatric patients, or those with conditions like dysphagia.

Recognizing the significance of FDTs, the European Pharmacopoeia (EP) has officially recognized them as “oral dissolving tablets," highlighting their acceptance in both academic and industrial settings. The article delves into the anatomical and physiological characteristics of the oral cavity, shedding light on the buccal epithelium, oral mucosa vascularization, and salivary flow, which play crucial roles in drug absorption.

The ideal features of FDTs include rapid dissolution or disintegration, high drug load capacity, masking of bitter taste, positive mouth feel, ease of transport, and reduced sensitivity to environmental factors. The advantages of FDTs extend to their administration for patients unable to swallow, convenient treatment for bedridden and mobile patients, enhanced mouth feel and taste masking, ease of administration, and precise dosing.

Despite their advantages, FDTs come with limitations, including issues related to mechanical strength, hygroscopic nature, brittleness, and challenges with bitter drugs or unpleasant odors. Overcoming these challenges requires a careful formulation approach to balance rapid disintegration with mechanical strength and taste masking.

The article also discusses the salient characteristics of Fast Dissolving Dosage Forms (FDDDS) and various techniques for preparing FDTs, such as freeze-drying, tablet molding, and spray drying. Additionally, it explores the role of non-invasive drug delivery systems in addressing pharmaceutical industry needs, including improving drug half-life, solubility/stability, and bioavailability.

口服给药领域取得了重大进展,其重点是开发创新配方,以应对与传统剂型相关的挑战,尤其是对吞咽困难的患者而言。本文探讨了速溶片剂的独特性质、优势和潜在应用,强调了速溶片剂在克服传统口服给药系统带来的挑战方面的作用。FDT 可在颊腔内 15-120 秒内快速溶解,有利于通过颊粘膜直接吸收,确保快速产生疗效。欧洲药典》(European Pharmacopoeia,EP)认识到 FDTs 的重要性,已正式将其认定为 "口腔溶解片",这表明学术界和工业界都认可这种药物。文章深入探讨了口腔的解剖和生理特点,揭示了颊上皮、口腔黏膜血管和唾液流等在药物吸收中起关键作用的因素。FDTs 的理想特性包括快速溶解或崩解、高载药量、掩盖苦味、良好的口感、易于运输以及降低对环境因素的敏感性。尽管具有这些优点,但 FDT 也有其局限性,包括与机械强度、吸湿性、脆性有关的问题,以及苦味药物或难闻气味方面的挑战。文章还讨论了速溶制剂(FDDDS)的突出特点以及制备速溶制剂的各种技术,如冷冻干燥、片剂成型和喷雾干燥。此外,文章还探讨了非侵入性给药系统在满足制药业需求方面的作用,包括改善药物半衰期、溶解度/稳定性和生物利用度。
{"title":"Advancing oral drug delivery: The science of fast dissolving tablets (FDTs)","authors":"","doi":"10.1016/j.ipha.2024.01.011","DOIUrl":"10.1016/j.ipha.2024.01.011","url":null,"abstract":"<div><p>The field of oral drug delivery has witnessed significant advancements, with a focus on developing innovative formulations to address challenges associated with traditional dosage forms, especially for patients with difficulties in swallowing. Fast Dissolving Tablets (FDTs) have emerged as a promising class of tablets designed to rapidly disintegrate or dissolve in saliva, providing a convenient and patient-friendly alternative for various populations.</p><p>This article explores the unique properties, advantages, and potential applications of FDTs, emphasizing their role in overcoming challenges posed by conventional oral drug delivery systems. FDTs offer rapid dissolution within 15-120 seconds in the buccal cavity, facilitating direct absorption through the buccal mucosa and ensuring quick therapeutic effects. This characteristic proves particularly beneficial for individuals facing swallowing challenges, such as pediatric and geriatric patients, or those with conditions like dysphagia.</p><p>Recognizing the significance of FDTs, the European Pharmacopoeia (EP) has officially recognized them as “oral dissolving tablets,\" highlighting their acceptance in both academic and industrial settings. The article delves into the anatomical and physiological characteristics of the oral cavity, shedding light on the buccal epithelium, oral mucosa vascularization, and salivary flow, which play crucial roles in drug absorption.</p><p>The ideal features of FDTs include rapid dissolution or disintegration, high drug load capacity, masking of bitter taste, positive mouth feel, ease of transport, and reduced sensitivity to environmental factors. The advantages of FDTs extend to their administration for patients unable to swallow, convenient treatment for bedridden and mobile patients, enhanced mouth feel and taste masking, ease of administration, and precise dosing.</p><p>Despite their advantages, FDTs come with limitations, including issues related to mechanical strength, hygroscopic nature, brittleness, and challenges with bitter drugs or unpleasant odors. Overcoming these challenges requires a careful formulation approach to balance rapid disintegration with mechanical strength and taste masking.</p><p>The article also discusses the salient characteristics of Fast Dissolving Dosage Forms (FDDDS) and various techniques for preparing FDTs, such as freeze-drying, tablet molding, and spray drying. Additionally, it explores the role of non-invasive drug delivery systems in addressing pharmaceutical industry needs, including improving drug half-life, solubility/stability, and bioavailability.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 580-587"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X24000212/pdfft?md5=e5cec6d258d3bad65a1e92c82c1b4b2c&pid=1-s2.0-S2949866X24000212-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139874102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional composition, antioxidant properties, and molecular docking strategy of muricidae operculum (Chicoreus ramosus) 鼠厣的营养成分、抗氧化性和分子对接策略
Pub Date : 2024-08-01 DOI: 10.1016/j.ipha.2023.11.006

The murrcidae gastropod operculum has many therapeutic uses in ayurveda, including treating cancer, gastric, hepatic, cardiovascular, and immunological disorders. Antibacterial, cell reinforcement, FTIR, and mass spectrum datas were used to identify important functional groups and chemical constituents in Chicoreus ramosus operculum concentrate. At 100 ​mg/L, the operculum extract showed stronger inhibitory movement (125 ​mm) against Bacillus subtilis and less (08 ​mm) against Staphylococcus aureus. Operculum extract's biochemical composition, total antioxidant properties, protein denaturation, metal chelation movement, all-out cell reinforcement action, and anti-diabetic action were 85.71%, 80.98%, 32.03%, and 76.47% at 1000 ​μg/mL concentration. The operculum remove FTIR showed nine significant groups, including amines, esters, and fragrant mixtures. 11 dynamic mixtures from GC–MS analysis of operculum rough concentrate. These bioactive fractions interacted with IL 23 in molecular docking experiments. Androst-1-en-3-one, Bis (2-ethylhexyl) phthalate, and 3-Methoxy-2,4,5-trifluorobenzoic acid had the highest docking scores and target protein receptor interactions. −11.9 ​kcal/mol, −08.6 ​kcal/mol and −7.7 ​kcal/mol are the maximum scores. These compounds are therapeutic and antimicrobial. These bioactive compounds in operculum extracts allow C. ramosus to be used in conventional medicine and may lead to the development of new drugs.

在阿育吠陀医学中,腹足纲厣壳有许多治疗用途,包括治疗癌症、胃病、肝病、心血管疾病和免疫疾病。本研究利用抗菌、细胞强化、傅立叶变换红外光谱和质谱数据来确定蓖麻苣苔厣壳浓缩物中的重要功能基团和化学成分。在 100 毫克/升的浓度下,厣提取物对枯草杆菌的抑制作用较强(125 毫米),而对金黄色葡萄球菌的抑制作用较弱(08 毫米)。在 1000 μg/mL 浓度下,厣壳提取物的生化成分、总抗氧化性、蛋白质变性、金属螯合作用、细胞全面强化作用和抗糖尿病作用分别为 85.71%、80.98%、32.03% 和 76.47%。去除厣的傅立叶变换红外光谱显示出 9 个重要基团,包括胺类、酯类和芳香混合物。从厣壳粗浓缩物的气相色谱-质谱分析中得出 11 种动态混合物。在分子对接实验中,这些生物活性馏分与 IL 23 发生了相互作用。雄甾-1-烯-3-酮、邻苯二甲酸二(2-乙基己酯)和 3-甲氧基-2,4,5-三氟苯甲酸的对接得分和目标蛋白受体相互作用最高。最高得分分别为-11.9 kcal/mol、-08.6 kcal/mol 和 -7.7 kcal/mol。这些化合物具有治疗和抗菌作用。厣提取物中的这些生物活性化合物可用于传统医学,并有可能开发出新药。
{"title":"Nutritional composition, antioxidant properties, and molecular docking strategy of muricidae operculum (Chicoreus ramosus)","authors":"","doi":"10.1016/j.ipha.2023.11.006","DOIUrl":"10.1016/j.ipha.2023.11.006","url":null,"abstract":"<div><p>The murrcidae gastropod operculum has many therapeutic uses in ayurveda, including treating cancer, gastric, hepatic, cardiovascular, and immunological disorders. Antibacterial, cell reinforcement, FTIR, and mass spectrum datas were used to identify important functional groups and chemical constituents in <em>Chicoreus ramosus</em> operculum concentrate. At 100 ​mg/L, the operculum extract showed stronger inhibitory movement (125 ​mm) against <em>Bacillus subtilis</em> and less (08 ​mm) against <em>Staphylococcus aureus</em>. Operculum extract's biochemical composition, total antioxidant properties, protein denaturation, metal chelation movement, all-out cell reinforcement action, and anti-diabetic action were 85.71%, 80.98%, 32.03%, and 76.47% at 1000 ​μg/mL concentration. The operculum remove FTIR showed nine significant groups, including amines, esters, and fragrant mixtures. 11 dynamic mixtures from GC–MS analysis of operculum rough concentrate. These bioactive fractions interacted with IL 23 in molecular docking experiments. Androst-1-en-3-one, Bis (2-ethylhexyl) phthalate, and 3-Methoxy-2,4,5-trifluorobenzoic acid had the highest docking scores and target protein receptor interactions. −11.9 ​kcal/mol, −08.6 ​kcal/mol and −7.7 ​kcal/mol are the maximum scores. These compounds are therapeutic and antimicrobial. These bioactive compounds in operculum extracts allow <em>C. ramosus</em> to be used in conventional medicine and may lead to the development of new drugs.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 485-494"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X2300120X/pdfft?md5=f6d95fc4786d937e192d5d0daebbc96f&pid=1-s2.0-S2949866X2300120X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139015034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Intelligent Pharmacy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1